Nicox SA (OTCMKTS:NICXF) Sees Significant Increase in Short Interest

Nicox SA (OTCMKTS:NICXF) saw a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 20,021 shares, an increase of 95,238.1% from the January 29th total of 21 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days. Currently, 0.0% of the company’s stock are short sold.

Nicox Price Performance

Shares of NICXF opened at $0.30 on Thursday. The stock has a 50-day moving average price of $0.30 and a 200 day moving average price of $0.30. Nicox has a one year low of $0.25 and a one year high of $0.30.

About Nicox

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.